The International Intra-Ocular Implant Club (IIIC)

STAAR Surgical to Report Third Quarter Results on November 2, 2022

Retrieved on: 
Wednesday, October 19, 2022
Surgery, Medical Devices, Hospitals, Health, Optical, Webcast, Lens, NASDAQ, Patient, ICL, Lens (anatomy), The International Intra-Ocular Implant Club (IIIC), Access, Eye, Replay, STAAR, Medical device

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 30, 2022 on Wednesday, November 2, 2022 after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 30, 2022 on Wednesday, November 2, 2022 after the market close.
  • STAAR will host a conference call and webcast on Wednesday, November 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call (Access Code 976076), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

STAAR Surgical to Report Second Quarter Results on August 10, 2022

Retrieved on: 
Wednesday, July 20, 2022
Surgery, Medical Devices, Health, Optical, Medical Supplies, Eye, Lens (anatomy), Lens, ICL, STAAR, Replay, The International Intra-Ocular Implant Club (IIIC), NASDAQ, Access, Webcast, Patient, Medical device

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close.
  • STAAR will host a conference call and webcast on Wednesday, August 10 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call (Access Code 904311), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)

Retrieved on: 
Tuesday, June 7, 2022
Optical, Health, Surgery, Medical Devices, ICL, Packer, Eye, Astigmatism, Lens (anatomy), American Academy, CEO, American Academy of Ophthalmology, Lens, Myopia, The International Intra-Ocular Implant Club (IIIC), Multimedia, EVO, Growth, Intraocular lens, Patient, Review, STAAR, Quality of life, NASDAQ, Literature, Safety, Medical device, Ophthalmology

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian Implantable Collamer lenses (ICLs) have been sold globally, including more than one and a half million of the companys latest generation of implantable lenses EVO Visian ICLs (EVO).

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian Implantable Collamer lenses (ICLs) have been sold globally, including more than one and a half million of the companys latest generation of implantable lenses EVO Visian ICLs (EVO).
  • This most recent milestone follows the initial successful stages of commercialization of our EVO lenses in the US.
  • Packer, The Implantable Collamer Lens with a central port: review of the literature, Clinical Ophthalmology, 2018.
  • STAARs lens used in refractive surgery is called an Implantable Collamer Lens or ICL, which includes the EVO Visian ICL product line.

STAAR Surgical to Report First Quarter Results on May 4, 2022

Retrieved on: 
Wednesday, April 20, 2022
Health, Medical Devices, Surgery, Manufacturing, General Health, Other Manufacturing, Optical, The International Intra-Ocular Implant Club (IIIC), ICL, Eye, NASDAQ, Replay, Lens (anatomy), Patient, STAAR, Webcast, Access, Lens, Medical device

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2022 on Wednesday, May 4, 2022 after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2022 on Wednesday, May 4, 2022 after the market close.
  • STAAR will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call (Access Code 592913), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S.

Retrieved on: 
Wednesday, April 6, 2022
Optical, Health, Surgery, Medical Devices, Myopia, Glasses, Company, Lens, NASDAQ, State, STAAR, Cataract, ASCRS, Multimedia, Glaucoma, Posterior, Panel, Program, Astigmatism, Lens (anatomy), Nursing, CEO, Cornea, Inflammation, Surgeon, Society, ICL, Eye, EVO, Female, The International Intra-Ocular Implant Club (IIIC), Patient, Medical device, Nightclub, Paper (disambiguation)

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first implants of the EVO Visian Implantable Collamer lens (EVO ICL) in the U.S.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first implants of the EVO Visian Implantable Collamer lens (EVO ICL) in the U.S.
  • She received toric EVO ICL lenses to achieve Visual Freedom and break free from contact lenses and glasses.
  • STAARs lens used in refractive surgery is called an Implantable Collamer Lens or ICL, which includes the EVO Visian ICL product line.
  • Since implantation of the EVO Visian ICL is a surgical procedure, before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications.

STAAR Surgical to Report Fourth Quarter and Fiscal Year Results on February 23, 2022

Retrieved on: 
Wednesday, February 9, 2022
Optical, Health, Surgery, Medical Devices, NASDAQ, Lens, Eye, The International Intra-Ocular Implant Club (IIIC), Replay, STAAR, ICL, Patient, Lens (anatomy), Access, Webcast, Medical device

STAAR will host a conference call and webcast on Wednesday, February 23 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.

Key Points: 
  • STAAR will host a conference call and webcast on Wednesday, February 23 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call (Access Code 142350), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .
  • More than 1,000,000 Visian ICLs have been implanted to date and STAAR markets these lenses in over 75 countries.

STAAR Surgical to Report Third Quarter Results on November 3, 2021

Retrieved on: 
Wednesday, October 20, 2021
Optical, Health, Surgery, Medical Devices, The International Intra-Ocular Implant Club (IIIC), NASDAQ, Eye, Lens, Access, Webcast, Replay, ICL, Patient, STAAR, Lens (anatomy), Medical device

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 1, 2021 on Wednesday, November 3, 2021 after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 1, 2021 on Wednesday, November 3, 2021 after the market close.
  • STAAR will host a conference call and webcast on Wednesday, November 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call (Access Code 249252), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .